Company: LIMN
Filing Date: 2025-01-16
Form Type: POS AM
Source: 0001104659-25-003835
Chunk: 310

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-16
Form: POS AM
Chunk 310
---
, stockholders would have received a redemption price of approximately $11.47 per share (net of all applicable taxes payable from the Trust Account) of Iris Class A Common Stock. If a public stockholder exercises its redemption rights, then it will be exchanging its redeemed Iris Class A Common Stock for cash and will no longer own such shares. Any request to redeem Iris Class A Common Stock, once made, may be withdrawn at any time until the deadline for requesting to exercise redemption rights requests and thereafter, with Iris’s consent, until the closing. Furthermore, if a holder of Iris Class A Common Stock delivers its certificate in connection with an election of its redemption and subsequently decides prior to the applicable date not to elect to exercise such rights, it may simply request that Iris’s Transfer Agent return the certificate (physically or electronically). The holder can make such request by contacting Iris’s Transfer Agent, at the address or email address listed in this proxy statement/prospectus. Iris will be required to honor such request only if made prior to the deadline for requesting to exercise redemption rights.

Notwithstanding the foregoing, a public stockholder, together with any affiliate of such public stockholder or any other person with whom such public stockholder is acting in concert or as a “group” (as defined in Section 13 of the Exchange Act), will be restricted from redeeming its shares with respect to

<div align='center'>162</div>

TABLE OF CONTENTS

more than an aggregate of 15% of the shares sold in Iris’s IPO, without Iris’s prior consent. Accordingly, if a public stockholder, alone or acting in concert or as a group, seeks to redeem more than 15% of the shares sold in Iris’s IPO, then any such shares in excess of that 15% limit would not be redeemed for cash, without Iris’s prior consent.

In order for public stockholders to exercise their redemption rights in respect of the Business Combination Proposal, public stockholders must properly exercise their redemption rights and deliver their stock certificates or shares of stock (electronically using The Depository Trust Company’s DWAC (Deposit/ Withdrawal At Custodian) system) to Iris’s Transfer Agent prior to , Eastern Time, on , 2025 (two business days prior to the vote on the proposal to approve the Business Combination). Promptly following the consummation of the Business Combination, Iris will satisfy the exercise of redemption rights by redeeming the shares of Iris Class A Common Stock issued to the public stockholders that validly exercised their redemption rights